NCT00396864 - Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

CancerLymphomas

Interventions

DRUG

NPI-0052

NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

77030

Univ. of Texas MD Anderson Cancer Center, Houston

85260

Premiere Oncology of America, Scottsdale